NASH is a worldwide epidemic disease affecting over 115 million people. Still, NASH remains an underdiagnosed and consequently an underreported disease. Untreated NASH may lead to cirrhosis, liver cancer and liver transplantation.
Our mission
The Swiss NASH Foundation is a non-for-profit organization committed to the dissemination of knowledge and raising of awareness about NASH. Through funding cutting edge research projects and increasing the knowledge and awareness about NASH, the foundation aims at contributing to treatment discovery as well as improving the patients’ quality of life.
Our history
In a joint effort to tackle the increasing prevalence and burden of NASH, scientific experts and the leading pharmaceutical companies: Gilead, Allergan, Genfit and Intercept have joined forces to establish The Swiss NASH Foundation.
Our vision
Prevent, diagnose and cure NASH.
Find out more
Swiss NASH Foundation: Mission and goals
News
- Is MASLD a Nighttime Disease? New Insights from Dr. Thomas Marjot’s ResearchAsk the author session Metabolic dysfunction–associated steatotic liver disease (MASLD) continues to challenge clinicians and researchers worldwide. While much is known about its links to… Read more: Is MASLD a Nighttime Disease? New Insights from Dr. Thomas Marjot’s Research
- How Fasting-Driven Microbiota Changes May Protect the Brain in Obesity: A Fascinating Conversation With Dr. Virginia MelaAsk the author session Understanding how our gut influences our brain is one of the most exciting frontiers in metabolic and liver-related research. For people… Read more: How Fasting-Driven Microbiota Changes May Protect the Brain in Obesity: A Fascinating Conversation With Dr. Virginia Mela
- Ask The Author: Unpacking Real-World GLP-1 Use with Dr. Jason SamuelsTracking GLP-1 Success: How Real-World Weight Loss Mirrors Clinical Trial Results—If Persistence Is Maintained We are excited to invite you to watch a short, insightful… Read more: Ask The Author: Unpacking Real-World GLP-1 Use with Dr. Jason Samuels
Living with NASH
Non-alcoholic steatohepatitis (NASH) is the consequence of abnormal fat accumulation in the liver leading to liver inflammation and damage. It is the most severe form of non-alcoholic liver disease (NAFLD), commonly called “fatty liver”. NASH is a worldwide epidemic disease affecting over 115 million people.
Still, NASH remains an under-diagnosed and consequently an underreported disease.
Many people live with NASH without knowing that they have a liver disease. The quality of life of these persons might be reduced due to their liver condition. Lifestyles can do a lot to improve NASH.
But changes in diet habits, regular physical activity are measures which can improve if not cure NASH.
